Chewy, Inc. (NYSE: CHWY) — A Real Margin-Expansion Story, Marked Down as a Broken Growth Stock, With Stock Comp Quietly Taxing the Cash Flow

Report date: 2026-07-04 · Sector: Consumer Discretionary · Internet & Direct-Marketing Retail (Pet) · Fiscal year ends late January. The analysis below carries no recommendation and no price target. The single exception is the labeled Claude's Take block that opens this article.

⚡ Claude’s Take

The author’s own independent opinion and general information — not investment advice. The analytical body below takes no position and contains no price target.

Verdict: HOLD — accumulate on further weakness (sub-~$18–20); fair-value zone ~$24–30. Not a short here; not a table-pounding long either. Conviction: medium. Tag: “The annuity works — the growth doesn’t, and the comp bill is real.”

Chewy is a genuinely better business than its chart says, and a worse one than its bulls claim. The good, first: this is a scaled (~$12.6B revenue), category-leading, ~84%-recurring (Autoship) online pet platform that has done exactly what a maturing e-commerce name is supposed to do — converted negative operating margins into a real, expanding profit and free-cash-flow stream. Gross margin has climbed every single year from 25.5% (FY2020) to 29.8% (FY2025) on a mix that is structurally improving: high-margin sponsored-ads revenue, private brands, and a deliberate push into pet health/pharmacy and Chewy Vet Care. Adjusted EBITDA margin has gone 1.5%→5.7%→a Q1-FY26 run-rate of 7.5%, against a credible 10% long-term target. The stock, meanwhile, trades at ~0.66x EV/sales — the cheapest in its public life (it was 5.8x at the 2021 peak, ~1.9x in FY2022), and roughly 15x reported free cash flow (~6.6% FCF yield). Down ~82% from its 2021 bubble high, it is a textbook falling knife the market has left for dead.

Now the discipline. Two things stop me from pounding the table. (1) The growth engine has genuinely downshifted — revenue growth has decelerated 25%→13%→10%→6%→6%, active customers grow only ~3.6%, and on June 10, 2026 management cut the FY26 revenue guide (to $13.4–13.55B from $13.6–13.75B) citing a “discerning consumer” and pressure on premiumization/attach rates. A pet retailer whose whole re-rating case rests on volume + NSPAC compounding is telling you the NSPAC compounding just stalled. (2) The free cash flow is flattered by stock-based comp. Record FY2025 FCF of ~$562M is struck after adding back a full ~$298M of SBC — comp that alone exceeds GAAP net income of $223M. Net of SBC, “owner” cash generation is ~$265M and the yield is ~3.5%, not 6.6%. Management is buying back stock (~$257M FY2025, ~$200M in Q1 FY2026) at a pace that essentially matches the SBC — it offsets dilution rather than shrinking the count. So the honest read is: cheap on sales and on reported FCF, only fair on economically-adjusted FCF, and optically expensive on GAAP earnings (~40x) and GAAP EBITDA (~22x) precisely because margins are still early in their climb. What flips me bullish: evidence NSPAC re-accelerates (health/vet/private-brand mix reasserting) while the 10% EBITDA path holds — that’s a double on earnings power at an unchanged multiple. What flips me bearish: Autoship growth cracking below high-single-digits or the consumer softness proving structural rather than cyclical, which would expose the absence of a wide moat versus Amazon and Walmart. At ~$21, most of the bad news is in the price and the cash flow is real — hence HOLD/accumulate, not chase.

📈 Stock Price Action — Five-Year Event Map

Chewy priced its IPO at $22/share on June 14, 2019 and rode the COVID pet-adoption boom and 2020–21 growth/meme mania to an all-time-high close of $118.69 on Feb 12, 2021 (~5.4x the IPO). What followed was a brutal, multi-year de-rating to an all-time-low close of $14.99 on Apr 30, 2024 (−87% off the high), a 2024–25 profitability-driven recovery that peaked near $48 (Jun 6, 2025), then a renewed roll-over on soft FY2026 guidance to a fresh cycle low of $17.51 on Jun 22, 2026. It last traded $20.85 (Jul 2, 2026) — −82.4% below the Feb-2021 peak and −50.7% below its 52-week high of $42.33. The 52-week range is $17.51 – $42.33. In plain terms: a full round-trip that erased essentially all of the pandemic-era re-rating, leaving the stock barely above its IPO price seven years on.

Cycle narrative. (1) Off the COVID trough the stock ran ~270% to its $118.69 peak as pandemic pet adoption and the Autoship-annuity narrative met peak risk appetite. (2) A ~77% collapse followed as the 2021–22 growth/rate de-rating hit an unprofitable name hardest. (3) Two sharp counter-trend squeezes (+40% Jun-22, +26% Oct-22) looked meme-driven, not fundamental — the downtrend resumed after each. (4) A ~54% grind carried the stock to its $14.99 all-time low (Apr 30, 2024) on decelerating customer growth. (5) The single sharpest reversal in the dataset (+41.5% in May-24 alone) coincided with the GAAP-profitability pivot and Keith Gill’s 6.6%-stake disclosure; it faded fast. (6) A more durable, fundamentals-led recovery on the margin/FCF story lifted the stock to a ~$48 peak (Jun 6, 2025), repeatedly capped by sponsor secondary offerings. (7) A ~64% give-back to a fresh 2-year low, driven by the Q4-FY25 print (a brief +13% pop that unwound) and the Q1-FY26 print, where “discerning consumer” caution and a revenue-guide cut reset expectations. Trend as of Jul 2, 2026: price below the 50-EMA ($21.31) and 200-EMA ($27.37), EMAs stacked bearishly (21<50<200); beta ~1.06; RS 12-month ~−50%. Price moves are FACT; attributed drivers are INTERPRETATION. No target, no recommendation here — that judgment lives in Claude’s Take above.

1. Executive Summary

Chewy is the largest pure-play online pet retailer in the United States, with ~$12.6B in FY2025 (Chewy’s fiscal year ended Feb 1, 2026) net sales, ~21.5M active customers, and a business model anchored on Autoship — an auto-replenishment subscription that now drives ~84% of net sales and grows faster than the company as a whole. The core proposition — convenience, competitive pricing, deep assortment, and genuinely differentiated customer service in an emotionally-driven, non-discretionary category — is real and defensible against most competitors. It is not obviously defensible against the two scaled generalists (Amazon, Walmart) that can match price and logistics; Chewy’s edge is category focus, service, and the switching-cost stickiness of an established Autoship relationship, not a structural cost or network moat.

The investment tension is a clean one. On the positive side: this is a maturing platform executing a credible margin-expansion story. Gross margin has risen every year (25.5%→29.8% over five years) on a structurally richer mix — sponsored ads (a high-margin retail-media stream), private brands (~500bp above the base), and pet health/pharmacy/vet care. GAAP operating income turned positive in FY2023, and reached $254M (2.0% margin) in FY2025; adjusted EBITDA margin has moved from ~1.5% to 5.7% (FY2025) with a Q1-FY2026 run-rate of 7.5% and a 10% long-term target. Free cash flow is real and growing (a record ~$562M in FY2025, on ~$692M operating cash flow less ~$129M capex), capex is light (~1% of sales), the balance sheet is net-cash, and the working-capital cycle is negative (suppliers finance inventory). On the negative side: growth has decelerated sharply to mid-single digits, active-customer growth is only ~3.6%, management cut the FY2026 revenue guide in June 2026 on consumer softness, and — critically — reported free cash flow is materially flattered by ~$298M of stock-based compensation, which exceeds GAAP net income; buybacks largely offset dilution rather than shrinking the share count.

Valuation reflects the market’s verdict that Chewy is a decelerating retailer, not a compounder: ~0.65x EV/sales (cheapest in its public history; ~6th percentile of its own range), ~15x reported FCF (~6.6% yield), ~40x GAAP earnings. Net of the ~$298M SBC add-back, the true FCF yield is closer to ~3.5%. The bull case is that the market is under-pricing a durable 84%-recurring annuity with a multi-year runway to a 10% EBITDA margin; the bear case is that a low-margin, no-wide-moat reseller facing Amazon/Walmart, growing revenue at 6% with a self-funded comp bill, is worth roughly what it trades for. This memo takes no house position; it lays out the evidence for both.

2. Business Overview

What Chewy does. Chewy is an e-commerce retailer focused exclusively on the pet category. It sells pet food and treats, supplies (beds, toys, crates, litter), pet medications and health products, and — increasingly — pet health services (telehealth, insurance/wellness plans via partners, and its own veterinary clinics). Founded in 2011 in Florida and now headquartered in Plantation, FL, it went public in June 2019. Substantially all revenue is generated in the United States; a small Canadian operation launched in 2023.

How it makes money. Chewy is a first-party retailer: it buys inventory and resells it, earning a gross margin on the spread, supplemented by higher-margin ancillary streams. The revenue architecture has three layers:

1. Consumables and health (the recurring core). Pet food, treats, and medications are consumable, non-discretionary, and highly repeatable — the ideal substrate for subscription. This is the bulk of revenue and the engine of Autoship.
2. Hardgoods (discretionary supplies). Beds, toys, tech, crates — lumpier, more discretionary, lower-repeat, but important for engagement and basket size.
3. High-margin ancillaries (the margin story). Sponsored ads (Chewy’s retail-media network — suppliers paying for placement, ~90%+ incremental margin), private brands (owned labels at ~500bp higher gross margin than national brands), Chewy Pharmacy (prescription and OTC pet meds), and Chewy Vet Care (CVC) clinics plus health services. These are the deliberate mix-shift levers behind gross-margin expansion.

Autoship — the defining feature. Autoship is auto-replenishment: customers schedule recurring deliveries of food/meds/supplies at chosen intervals, at a small discount. It reached 84.4% of net sales in Q1 FY2026 and grows faster than total revenue (Autoship sales +10–14% vs. total +6–8%). This is the single most important fact about the business — it converts a commoditized reselling operation into a recurring-revenue annuity with high visibility, low churn, and structurally lower acquisition cost per incremental dollar. Management describes the model as a “flywheel”: acquire a customer, migrate them to Autoship, deepen the relationship into health/vet/private brands, and compound net sales per active customer (NSPAC).

Key operating metrics (the ones that matter).

• Active customers: ~21.5M (Q1 FY26), +3.6% YoY. Net adds guided to ~150–250k/quarter (now trending to the low end).
• NSPAC (net sales per active customer, trailing 12M): $597 in Q1 FY26, +4.6% normalized. This is the “revenue-per-relationship” lever and the one currently under pressure.
• Autoship % of net sales: 84.4%.
• Gross margin: 30.1% Q1 FY2026 / 29.8% FY2025.

Revenue segmentation. Chewy does not report granular product segments; it discloses net sales, Autoship penetration, active customers, and NSPAC. Directionally: consumables + health dominate; hardgoods are a minority and more cyclical; the ancillary/health/ads streams are small in dollars but disproportionately important to margin. Verdict: a scaled, focused, overwhelmingly-recurring first-party pet e-tailer whose revenue quality (recurring, non-discretionary) is well above the average retailer, but whose core margin structure is that of a reseller, not a marketplace or software business.

3. Industry Dynamics

The pet category is structurally attractive — but not uniquely profitable. U.S. pet spending is large (~$150B+ across food, supplies, vet care, and services) and has grown resiliently through cycles on the back of pet humanization (owners treating pets as family, trading up to premium food, health, and services) and the non-discretionary, emotionally-driven nature of core spend. Management frames 2026 as “steady and resilient… without cyclical acceleration,” expecting low-single-digit industry growth, predominantly volume-driven with little pricing — an important admission that the tailwind is now modest, not the double-digit COVID-era surge. Pet household formation is “stable with no evidence of deterioration,” but management is “not underwriting a meaningful rebound.”

The secular tailwind Chewy actually rides is e-commerce penetration of pet. Online penetration of pet spend continues to rise (convenience, auto-replenishment, price transparency), and scaled digital platforms capture a disproportionate share of that shift. This is real and durable, but it is a shared tailwind — Amazon and Walmart ride it too.

Competitive structure — this is where the industry rates only “fair.” The pet-retail value chain has several well-capitalized layers:

• Scaled online generalists — Amazon and Walmart. The existential competitive question. Both can match Chewy on price and increasingly on delivery speed; Amazon has Subscribe & Save (its own auto-replenish) and vast logistics. Chewy competes on category depth, pet-specific service (24/7 vet-staffed support, condolence cards, personalization), and the installed Autoship relationship — not on structural cost advantage.
• Big-box pet specialty — PetSmart (private, ex-parent) and Petco (WOOF). Omnichannel incumbents with services (grooming, vet). Petco is a weakened public competitor; PetSmart is Chewy’s former parent and remains a large offline player.
• Grocery/mass and vertical DTC brands (fresh-food players like The Farmer’s Dog, premium brands) at the edges.
• Veterinary care — a large (~$40B+ in-clinic products/services), fragmented, high-margin adjacency Chewy is entering directly (CVC clinics) and via partners; the incumbents are corporate consolidators (Mars/Banfield, VCA, National Veterinary Associates) and independents.

Profit pools and the Petco contrast — why “leader in a good category” ≠ “great business.” The pet category’s profit pool is unevenly distributed, and Chewy sits in a structurally low-margin slice of it. The richest economics accrue to the branded manufacturers and pet-health franchises — Zoetis (animal-health pharma, ~35%+ operating margins, wide moat) and IDEXX (veterinary diagnostics, ~30% operating margins, razor-and-blade lock-in) — not to the retailers who resell their products. Among retailers, Chewy is clearly the best-positioned: contrast Petco (WOOF), the closest scaled specialty competitor, which has struggled with declining comps, thin-to-negative profitability, elevated leverage, and a collapsed equity value — a cautionary tale of an omnichannel pet retailer without Chewy’s Autoship annuity or digital execution. That contrast validates Chewy’s operational superiority within retail. But being the best low-margin reseller in a category whose fat profits sit upstream (Zoetis/IDEXX) and whose scale-generalist competitors (Amazon/Walmart) will cap pricing is precisely why Chewy earns a 1.8% net margin while the pet-health names earn 20%+. The strategic logic of Chewy’s push into private brands, pharmacy, and vet care is, in effect, an attempt to migrate up the profit pool toward those richer economics — the single most important long-term strategic question for the business.

Marathon capital-cycle read. The pandemic pulled forward enormous capital and capacity into online pet (Chewy’s own fulfillment buildout, Petco’s omnichannel spend, fresh-food entrants). That capital has since been rationalized: promotional intensity normalized, weaker players retrenched, and Chewy itself pivoted from land-grab to margin harvest. The supply side is now more rational than in 2021 — supportive for Chewy’s margin expansion — but the demand side has cooled to low-single-digit volume growth, and the largest competitors (Amazon/Walmart) are not capital-constrained. Verdict: a structurally good category (resilient, recurring, humanization-driven) housed in a fair competitive structure. The economics are decent for the scaled leader but perpetually pressured by two generalists who will never let pet become a high-margin oligopoly. Good industry to be the leader in; not a fortress.

4. Competitive Position

Name the moat: switching costs (moderate) + intangibles/brand (real but narrow) + scale economies in fulfillment (necessary, not decisive). Chewy has a genuine but narrow competitive advantage, and it is important to be precise about its mechanism rather than accept the “flywheel” marketing framing.

• Switching costs / customer captivity (the strongest leg). Once a pet owner has set up Autoship — with saved pet profiles, medication records, dosage schedules, veterinary prescriptions on file, and a delivery cadence tuned to their household — the friction and cognitive cost of re-creating that elsewhere is real. Autoship at 84% of sales, growing double-digits, with NSPAC compounding across cohorts, is the financial fingerprint of captivity: mature cohorts keep spending more. In Greenwald’s taxonomy this is demand-side captivity by habit and switching cost — the most valuable of Chewy’s advantages, and the one that would show up as a revenue cliff if it disappeared.
• Intangibles / brand and service (real, narrow). Chewy has built a genuinely differentiated service reputation (24/7 support staffed with veterinary professionals, proactive gestures, category expertise) that national retailers do not replicate. This supports pricing parity without a price war and lowers churn. But brand loyalty in reselling commodities is shallow relative to, say, a consumer-staples brand: it earns share-of-wallet, not pricing power over the products themselves.
• Scale economies in fulfillment (table stakes). Chewy’s ~20-facility fulfillment network (including automated next-gen sites like Houston) and negative working-capital cycle give it cost efficiency at $12.6B of volume. But this is a necessary condition to compete, not a decisive edge — Amazon and Walmart have vastly larger, more automated networks. Scale here defends margins; it does not build a wall.
• Retail media / sponsored ads (an emerging, genuinely high-margin edge). As Chewy’s first-party data and traffic scale, its sponsored-ads business becomes a structurally high-margin, capital-light profit stream that a subscale competitor cannot replicate — this is the most attractive new source of advantage and the single biggest gross-margin driver. It is small today but strategically the best thing in the model.

The pressure test — network effects and durability. Management gestures at a “flywheel,” but there is no true network effect here: more customers do not directly make the service more valuable to other customers (unlike a marketplace). The advantages are captivity + service + retail-media scale, which are real but bounded. The market-share-stability test is passing but softening: Chewy keeps gaining category share (Autoship growth > market), yet active-customer growth of 3.6% and a June-2026 NSPAC stumble show the captivity is not immune to a weaker consumer trading down and cutting attach/premiumization.

Greenwald test — apply the framework honestly. Competition Demystified says a genuine competitive advantage shows up as stable or rising market share plus returns above the cost of capital, and that the only durable advantages are supply-side cost edges, demand-side captivity, and economies of scale combined with captivity. On the share test, Chewy passes: it has taken online pet share for years, and Autoship growth exceeding category growth is direct evidence of captivity holding. On the returns test, the picture is muddier — Chewy’s incremental economics (rising gross margin, ~19% incremental operating margin) are improving toward a return above cost of capital, but its current net margin (1.8%) and the SBC drag mean it is only now crossing into clear economic profit. The advantage it possesses is demand-side captivity (Autoship habit/switching cost) plus a nascent scale-economy-with-captivity dynamic in retail media — the two most durable types in Greenwald’s taxonomy — but it lacks the supply-side cost advantage against Amazon/Walmart that would make it unassailable. An earnings-power-value (EPV) lens is instructive: on ~$254M of current GAAP operating income (or ~$719M adjusted EBITDA less SBC), the business is worth meaningfully more than its tiny asset value, confirming a real franchise — but the EPV is highly sensitive to whether the margin climb to 10% is real, which is exactly the contested variable.

Head-to-head. Versus Petco: Chewy is clearly winning — better economics, cleaner balance sheet, superior digital execution. Versus Amazon/Walmart: Chewy holds share through focus and service, but has no structural cost or price advantage; it survives by being the best pet-specific experience, which is a defensible-but-not-widening position. Verdict: a durable but narrow moat — real customer captivity in Autoship plus a rising retail-media edge, hemmed in permanently by two generalist giants. This is a “good business at scale,” not a wide-moat compounder. The moat is sufficient to protect the margin-expansion thesis; it is not sufficient to guarantee re-acceleration of growth.

5. Growth History and Forward Opportunities

History — a decelerating S-curve. Revenue (Chewy fiscal-year convention): FY2020 $7.15B → FY2021 $8.97B (+25%) → FY2022 $10.12B (+13%) → FY2023 $11.15B (+10%) → FY2024 $11.86B (+6.4%) → FY2025 $12.60B (+6.2%). The trajectory is unambiguous: Chewy has transitioned from hyper-growth to mature single-digit growth in five years. Q1 FY2026 net sales grew 7.7% (aided by mix/timing), but management’s own FY2026 guide (~$13.4–13.55B) implies ~6–7% for the year — and was cut in June 2026.

The two-factor growth algorithm. Management decomposes growth into (a) active-customer growth (net adds) and (b) NSPAC expansion:

• Active customers troughed for growth in 2023–24, “inflected” to positive net adds in 2024, and ran ~810k net adds in FY25 to reach 21.3M, then 21.5M in Q1 FY26 (+3.6%). Net adds are now guided to the low end of the 150–250k/quarter range. This is low-single-digit growth — respectable for a mature leader, unexciting for a “growth” multiple.
• NSPAC ($597, +4.6% normalized) is the swing factor and the current problem child. The bull thesis leans heavily on NSPAC compounding via health/vet mix, private-brand penetration, and deeper engagement — but Q1 FY26 flagged “modest incremental pressure on premiumization and product attach rates,” i.e., the consumer is trading down and NSPAC growth slowed below plan.

Forward opportunities (ranked by credibility).

1. Pet health & Chewy Vet Care (the crown jewel of the growth story). Management sizes pet-health TAM at ~$54B (incl. ~$40B in-clinic products/services). CVC now has ~18 clinics (10–12 new/year), described as the “fastest NSPAC compounder”: ~40% of CVC customers are new to Chewy and reach ~$900 year-1 NSPAC (vs. ~$597 company average). The Modern Animal acquisition (Q1 FY26, EBITDA-neutral in 2026) and a “Practice Hub” partner model extend this. Credible and strategically sound — vet care both opens a huge TAM and deepens captivity — but it is capital- and execution-intensive and small today.
2. Private brands. Targeting low-to-mid-teens % of net sales (from a lower base) at ~500bp higher gross margin; new lines (Get Real fresh food, “Chewy Made”). Primarily a margin lever, secondarily NSPAC.
3. Sponsored ads / retail media. High-margin, scaling nicely; more a margin than a revenue-growth story, and management expects its incremental contribution to taper in 2026.
4. Chewy Plus (membership). A loyalty/membership program aimed at lifting retention and NSPAC; explicitly margin-neutral in 2026 — optionality, not yet a driver.
5. Canada / international and adjacencies (insurance, pharmacy). Small, early, optional.

Verdict: medium-quality growth, improving in mix but decelerating in rate. The quality of growth is rising (more recurring, more health, higher-margin), which is what you want. But the rate has fallen to mid-single-digits and the NSPAC lever — the one that makes the model compound — just stumbled. This is a business that will more likely grow revenue ~5–8% than re-accelerate to double digits, with the real profit growth coming from margin, not volume.

6. Financial Quality

This is the most important section for the thesis, because Chewy’s headline financials look better than its economic financials, and the gap is stock-based compensation.

Revenue quality — high. ~84% Autoship, non-discretionary, recurring, with a negative working-capital cycle (customers/suppliers effectively fund the business). Cash conversion cycle ~−8.5 days. This is genuinely high-quality, visible revenue.

The negative-working-capital engine — an underappreciated structural asset. Because Chewy collects from customers at (or near) the point of sale but pays suppliers on 30–60+ day terms, and because inventory turns quickly against a subscription-driven demand signal it can forecast precisely, the business runs a negative cash-conversion cycle. The financial fingerprint is in the cash-flow statement: operating cash flow ($691.6M in FY2025) consistently exceeds net income by a wide margin, with accounts-payable increases contributing $98M (FY2025), $181M (FY2024), and $224M (FY2023) to operating cash — i.e., growth is partly self-funding, as an expanding revenue base throws off supplier float. This is the same structural advantage Amazon and Costco enjoy, and it means Chewy needs very little balance-sheet capital to grow — a genuine, durable positive that supports the light-capex, cash-generative model. It also means the reverse is a risk in a sharp revenue decline: negative working capital unwinds and consumes cash if the top line ever contracts, though nothing in the current trajectory suggests that.

Cohort economics — the bull’s evidence and the bear’s caveat. Management’s disclosed cohort behavior is the crux of the quality argument. New customers enter at ~$150–200 first-year NSPAC and compound toward the ~$597 company average and beyond as they migrate to Autoship, add categories (health, pharmacy), and — for the highest-value cohorts (app-native, health-native, and especially Chewy Vet Care at ~$900 year-1 NSPAC) — compound faster still. Mature cohorts keep spending more each year, which is the textbook signature of demand-side captivity and the reason the “annuity” framing is legitimate. The caveat, freshly relevant after June 2026: NSPAC compounding is not immune to the macro — when the consumer trades down and cuts discretionary attach/premiumization, the compounding slows, as it just did. So the cohort machine is real but cyclically sensitive; the bull needs it to reassert, the bear thinks the reassertion keeps getting pushed out.

Margin structure — steadily improving, and the real story. (Chewy fiscal-year convention; each fiscal year ends the following late January/early February.)

*FY2024 GAAP net margin of 3.3% ($392.7M) is flattered by a ~$241M income-tax benefit (release of a deferred-tax-asset valuation allowance); FY2024 pretax income was only $151.7M. When the benefit did not recur, FY2025 GAAP net income fell to $222.8M — but this is a tax artifact, not operational deterioration: on an adjusted basis, net income actually rose from $446.8M (FY2024) to $540.5M (FY2025). Normalize the tax line before any earnings-trend read.

The gross-margin march (25.5%→29.8%, +430bp over five years) is the clean, real, durable positive — driven by sponsored ads, premium/health mix, private brands, and a rational promotional environment. Operating leverage is now compounding on top of it: GAAP operating income went −$24M (FY2023) → +$113M (FY2024) → +$254M (FY2025).

The SBC gotcha — read this twice. Stock-based compensation was ~$298M in FY2025 (2.4% of revenue) — larger than GAAP net income of $223M. SBC history: $239M (FY2023) → $306M (FY2024) → $298M (FY2025). Two consequences:

1. “Adjusted EBITDA” is materially inflated by adding SBC back. Reported adjusted EBITDA was $719M (5.7%) in FY2025 vs. GAAP EBITDA of only ~$384M; the gap is mostly SBC. When management guides to a “10% adjusted EBITDA margin,” a meaningful slice of that is comp added back, not cash economics.
2. Reported free cash flow is flattered. Record FY2025 FCF of ~$562M (operating cash flow $691.6M less $129.2M capex) is struck after adding back the full ~$298M of SBC. Economically-adjusted FCF (net of SBC) is ~$265M. That is still positive and growing — but it changes the FCF yield from ~6.6% to ~3.5% and the multiple from ~15x to ~32x. The buyback essentially matches SBC dollar-for-dollar — it funds dilution, not surplus return.

Free cash flow and capital intensity. Reported FCF (company definition, OCF less capex): ~$350M (FY2022) → ~$453M (FY2023) → ~$452M (FY2024) → ~$562M (FY2025, a record). Capex is light (~$129M, ~1% of sales) — a genuine asset-light advantage of the model. Even net of SBC, Chewy generates real cash; the point is calibration, not denial.

Returns on capital. Conventional ROE/ROIC are distorted by a negative retained-earnings/small-equity balance sheet (accumulated deficit −$1.36B from years of losses; total equity only ~$498M; book value ~$1.2/share). ROIC screens optically high (~24% on ROIC’s definition) precisely because the invested-capital base is tiny — this is a capital-light, negative-working-capital model, not a high-return-on-a-large-base compounder. The honest metric is FCF conversion and incremental margins: incremental operating margin ~19% is healthy and is the real evidence that economics improve with scale.

Balance sheet — strong. Cash ~$860M, only finance-lease debt ~$519M → net cash ~$341M. Negative cash-conversion cycle. Management signaled it will add “a modest amount of leverage” as an appropriate evolution — worth monitoring but not alarming at this scale of FCF. Verdict: economics genuinely improve with scale (rising gross margin + operating leverage + light capex + negative working capital), but the reported profitability and FCF overstate the true owner economics by the ~$300M SBC wedge. High-quality revenue; medium-quality reported earnings until SBC is normalized.

7. Capital Allocation

The framework management articulates. Grow profitably, expand margin, convert “at least 80% of profitability into free cash flow,” reinvest in high-ROI initiatives (Chewy Health, CVC, AI, fulfillment automation), and return the rest to shareholders via buybacks. On paper, disciplined and coherent.

Buybacks — the primary return, but largely a vehicle to absorb the sponsor’s exit and offset dilution. The board authorized a $500M repurchase program in May 2024 and added another $500M in April 2026 (leaving ~$550M of authority at May 2026). Cash deployed: ~$943M in FY2024 and ~$262M in FY2025 (~$257M / 6.8M shares), with ~$200M more in Q1 FY2026; management guided to increase activity in FY2026, citing valuation. Two critical caveats. First, a large share of the buyback has been repurchases made directly from BC Partners concurrent with its secondary offerings — e.g., $500M (June 2024), $300M at $29.40 (Sept 2024), $50M (Dec 2024), $100M at $41.75 (June 2025) — i.e., the company is spending shareholder cash to absorb the sponsor’s exit, not purely to shrink the float opportunistically. Second, against ~$298M/year of SBC, the buyback roughly neutralizes dilution rather than shrinking the count — shares outstanding have drifted only modestly (~407M in FY2020 to ~409M as of the May-2026 record date). So the “return of capital” is, in substance, largely the cash cost of the equity comp plus sponsor absorption. Buying back stock at ~0.65x sales is defensible if you believe the margin story; just don’t mistake it for surplus-capital return. There is no dividend (appropriate at this stage).

M&A and reinvestment — small, strategic, health-focused. Capital deployment into acquisitions has been modest and on-strategy: per management, Modern Animal (veterinary clinics/technology; EBITDA-neutral in 2026) and SmartPak (equine/health) in Q1 FY2026 (both small enough that no material-transaction 8-K appears in the corpus — treat terms as management-disclosed, not filing-confirmed), plus the organic Chewy Vet Care clinic buildout (10–12/year). The bulk of real capital allocation is reinvestment through the P&L — fulfillment automation, AI-enabled productivity, CVC clinics, private-brand development, sponsored-ads infrastructure — and with ~19% incremental operating margins and rising gross margin, it appears to be earning its keep. Capex is disciplined (~1% of sales). No large, dilutive, or off-strategy deals — a point in management’s favor.

New leverage — first real debt (June 2026). Historically net-cash with only an undrawn ABL, Chewy entered a 7-year $600M senior secured term loan on June 23, 2026 (JPMorgan agent; Term SOFR + 1.75%; 1%/yr amortization) — its first funded term debt, the concrete form of the “modest leverage” management flagged. At this FCF scale it is manageable, but it is a directional shift from a pure fortress balance sheet toward funding buybacks/optionality with debt, and worth monitoring.

Sponsor control and share structure (a real governance mark). This is stronger than a mere “overhang.” Chewy remains a BC Partners–controlled, dual-class company: as of the May-2026 record date there were ~232.5M Class A (1 vote) and ~176.5M Class B (10 votes) shares, with BC Partners owning 100% of the Class B — ~43% of the economics but ~88% of the total voting power. Chewy is still a “controlled company” under NYSE rules and uses the governance exemptions (no requirement for a majority-independent board; several directors, including the chairman, are BC Partners principals). There is no time-based dual-class sunset — control persists as long as Class B holds ≥50% of the vote. BC Partners converts Class B to Class A to sell into each secondary (which is why economics fall faster than votes), and certain BC Partners affiliates have pledged Class B shares as collateral for indebtedness (including PetSmart’s) — a default could force a change of control. Minority holders therefore own a genuinely non-controlling stake.

Insider behavior — no conviction buying. A sweep of all ~97 Form 4s filed since mid-2024 shows only grants (code A), tax-withholding (F), and open-market sales (S) — zero discretionary open-market purchases (code P) by any officer or director in ~two years. CEO Sumit Singh holds ~1.02M Class A (<1%); the former CFO held zero. The dominant insider flow is the sponsor’s registered selldowns. Net: no bullish insider signal at these depressed prices — a mild negative for a contrarian long. Verdict: competent and disciplined capital allocation in substance — light capex, on-strategy tuck-ins, no empire-building, opportunistic buybacks — but the buyback is best understood as funding the SBC bill and absorbing the sponsor’s exit; the dual-class/controlled-company governance is a real, structural mark against; and the new $600M term loan and absence of any insider buying temper the “deep-value” read.

8. Changes and Headwinds — Last Two Years

Strategic and operational changes.

• Pivot from growth to profitable growth (2023→present). The defining shift: Chewy stopped chasing revenue and began harvesting margin — gross-margin expansion, sponsored ads, private brands, opex discipline, fulfillment automation. This is the entire re-rating (and de-rating) story.
• Chewy Vet Care buildout + Modern Animal / SmartPak tuck-ins (2024–2026). Direct entry into veterinary services — the biggest strategic expansion, opening a ~$40B+ TAM and the highest-NSPAC customer cohort.
• Chewy Plus membership launch and Get Real / Chewy Made private-brand launches — NSPAC and margin levers.
• Heavy C-suite churn (a yellow flag). Former CFO David Reeder resigned in July 2025; Chris Deppe (internal) was appointed CFO effective February 2026; the Chief Accounting Officer was removed and the CTO departed in the same ~12-month window. CEO Sumit Singh remains in place, so strategy is continuous — but three finance/technology C-suite changes in a year is instability worth flagging.
• First real leverage: a 7-year $600M senior secured term loan (June 23, 2026) — the concrete form of the “modest leverage” management signaled, a shift from a pure net-cash posture.

Headwinds (the reasons the stock is at 2-year lows).

• Consumer softening / June 2026 guidance cut. The proximate catalyst: on June 10, 2026, Chewy beat Q1 EPS but cut FY2026 revenue guidance ($13.6–13.75B → $13.4–13.55B, vs. ~$13.84B consensus), citing a “discerning consumer,” weaker discretionary attachment, and pressure on premiumization/NSPAC. Net adds guided to the low end. Analysts cut price targets across the board (to $24–36). Importantly, management held the adjusted-EBITDA-margin guide (6.6–6.8%) — the margin story is intact; the volume story cracked.
• Growth deceleration to mid-single digits — structural, not one-off.
• Fuel surcharges from carrier partners pressuring gross margin modestly in FY26.
• Sponsor secondary overhang (BC Partners selldowns) — a recurring technical cap on the stock through 2024–25.
• Amazon/Walmart competitive intensity — a permanent, unquantifiable overhang.

Verdict: the last two years both strengthened and weakened the thesis. Strengthened: the margin/FCF model is proven and the health/vet strategy is credible and differentiated. Weakened: growth has structurally decelerated and the consumer has turned cautious, undermining the NSPAC-compounding half of the algorithm at exactly the moment the bulls needed it. Net: the quality of the business improved while the growth narrative broke — which is precisely why the stock is cheap.

9. Risk Analysis (Risk Matrix)

Overall: the dominant risks are fundamental-erosion (Amazon/Walmart + growth stall) and quality-of-earnings (SBC), not balance-sheet or solvency. This is a “value trap vs. cheap compounder” debate, not a bankruptcy candidate. Catastrophic loss risk is very low; the realistic downside is a slow de-rating if growth keeps fading.

10. Valuation Discussion (Embedded Expectations)

Where it trades (price $20.85; ~409M sh as of the May-2026 record date, ~426M diluted).

• Market cap ~$8.5B; net cash ~$0.3B (pre the June-2026 $600M term loan) → EV ~$8.2B.
• EV/sales ~0.65x — the cheapest in Chewy’s public history (5.8x at the FY2020 peak, 2.2x FY2021, 1.9x FY2022, ~0.9x at FY2025 year-end). AZI’s own-history percentile: P/S ~6th percentile, composite ~16th — near its cheapest-ever on sales.
• Reported FCF multiple ~15x (~6.6% FCF yield). But net of the ~$298M SBC add-back, ~32x (~3.5% yield).
• GAAP P/E ~40x; EV/GAAP-EBITDA ~21x (optically rich because margins are early).
• EV / forward adjusted EBITDA ~9x (on the FY2026 6.6–6.8% guide, ~$0.9B) — but that adjusted EBITDA adds back SBC.

The multiple set tells the whole story: cheap on sales and reported FCF, only fair on economically-adjusted FCF, expensive on GAAP earnings. Which number you anchor on is the bull/bear debate.

Embedded-expectations analysis — what the ~$8.3B EV is underwriting. At ~0.66x sales on a business growing ~6% with a credible path from ~6% to ~10% adjusted EBITDA margin, the market is pricing Chewy as a decelerating, low-margin reseller with a permanent Amazon/Walmart discount — not as a compounding platform. Reverse-engineered: if Chewy hits a 10% adjusted EBITDA margin on, say, ~$16B of revenue in 3–4 years (~7% CAGR), that’s ~$1.6B adjusted EBITDA; even net of ~$300M SBC (~$1.3B “real” EBITDA), a 10–12x multiple implies an EV of ~$13–16B — meaningful upside from ~$8.2B. For that to be wrong, one of two things must hold: either (a) growth keeps fading toward ~3–4% and the 10% margin proves unreachable (bear), or (b) SBC stays ~2.4% of revenue and the market correctly refuses to pay for cash flow it doesn’t actually keep (the quality-of-earnings discount is deserved).

Scenario sketch (illustrative, not a target).

• Bear: growth fades to ~3–4%, consumer weakness structural, margin stalls ~7–8%, SBC persists. Market keeps it at ~0.5–0.6x sales / low-double-digit reported FCF. Fair EV roughly flat-to-down from here.
• Base: ~6–7% growth, adjusted EBITDA margin marches toward 9–10%, SBC gradually declines as % of sales. Re-rates modestly to ~0.8–1.0x sales as the margin story is validated. Meaningful upside on the multiple and the earnings.
• Bull: NSPAC re-accelerates (health/vet/private-brand mix), growth returns to high-single/low-double digits, 10% margin achieved ahead of plan, SBC falls. Re-rates to ~1.2–1.5x sales — a double-plus.

Peer comp set (illustrative; multiples approximate and mixed FY conventions).

*Amazon’s consolidated multiple reflects AWS/ads; its retail-only economics are lower-margin. The table’s point: Chewy’s ~0.65x sits below Wayfair and roughly in line with the weakest retail comps, while the wide-moat pet-health names trade at 8–10x sales on structurally superior economics. Chewy is priced as a low-margin e-tailer, not as a pet-health compounder — the mispricing case is that its rising health/vet/retail-media mix deserves a multiple between the reseller and the compounder, not pinned at the reseller floor.

Comps discussion. Against covered peers: pet-health names ZTS and IDXX trade at premium multiples on genuinely wider moats and higher structural margins — not true comps, they’re the “quality” end of pet. The right comp set is scaled e-commerce/omnichannel retail (Amazon’s retail segment, Wayfair (W), etc.) plus specialty retailers — where ~0.6–0.7x sales for a 6%-grower with expanding margins and ~8% reported FCF yield is cheap but not absurdly so, precisely because the market applies a discount for the SBC wedge and the generalist threat. No price target; no recommendation. The embedded expectations are demonstrably low; whether they are too low depends entirely on the margin path and the durability of Autoship captivity.

11. Variant Perception

Consensus view. Sell-side is broadly constructive-but-trimmed: a cluster of Buy/Outperform/Overweight ratings with price targets recently cut to $24–36 after the June-2026 guide reduction (Baird $30, Barclays $36, TD Cowen $34, RBC $34, Goldman $34, JPMorgan $29, UBS $24, Citizens $28; Needham Hold). Consensus believes the margin story is real and the stock is cheap, but marked down its revenue estimates on the consumer. The market’s revealed view (0.66x sales, 2-year low) is more bearish than the sell-side — it is pricing a broken growth stock.

Strongest bull case. Chewy is a scaled, 84%-recurring, non-discretionary annuity trading at its cheapest-ever sales multiple, with a proven, still-early margin-expansion runway (6%→10% adjusted EBITDA), a genuinely differentiated and high-NSPAC health/vet growth vector, a rising high-margin retail-media business, light capex, negative working capital, and net cash. The consumer softness is cyclical; when it normalizes, both NSPAC and multiple re-rate, and the earnings power roughly doubles at an unchanged multiple. You’re being paid a ~6.6% reported FCF yield to wait.

Strongest bear case. Chewy is a low-margin (1.8% net) first-party reseller with no wide moat against Amazon and Walmart, whose growth has structurally decelerated to ~6% and whose flagship NSPAC-compounding lever just stalled. Reported FCF is a mirage: ~$298M of SBC (bigger than net income) means “owner” FCF is roughly half of reported and the real yield is ~3.5% at ~32x — not cheap for a decelerating retailer. The buyback funds dilution, not shareholders. The dual-class/sponsor overhang caps upside. This is a value trap: optically cheap on sales, fairly-to-fully valued on true economics, with a permanent competitive ceiling.

The 3–5 assumptions that actually decide it.

1. Does NSPAC re-accelerate? The single most important variable. Bull needs mix-shift (health/vet/private brand) to reassert; bear says the consumer trade-down is the new normal.
2. Is the 10% adjusted-EBITDA-margin path real and cash-backed? Or does sponsored-ads tapering + fuel + gross-margin moderation stall it near 7–8%, and how much is SBC add-back?
3. How durable is Autoship captivity against Amazon/Walmart over a multi-year horizon?
4. Does SBC decline as a % of revenue (making reported FCF converge to real FCF), or stay ~2.4%?
5. Is the consumer weakness cyclical or structural?

Falsification. Bull is falsified if: Autoship growth decelerates toward mid-single-digits and active-customer growth drops below ~3%, or adjusted EBITDA margin stalls below ~7.5% for a full year. Bear is falsified if: NSPAC growth re-accelerates above ~6% and the company hits ~8%+ adjusted EBITDA margin while SBC/revenue falls — proving the model compounds real per-share cash. Factor-positioning input: the tape is a multi-year falling knife (RS 12m ~−50%, ~82% off the 2021 high, all risk-adjusted return metrics negative, negative momentum loading) — consensus is maximally pessimistic on the price, which is where variant-perception upside can live if the fundamentals merely stabilize. The stock is priced for continued disappointment; it does not need to become great to work, only to stop deteriorating.

12. Fact vs. Interpretation Table

13. Open Questions

1. How much longer will BC Partners keep selling, and what is the pace? Ownership/control is now confirmed (~43% economics / ~88% votes, controlled company, no sunset), but the remaining ~176.5M Class B shares are a multi-year overhang; the selldown pace and any pledged-share/change-of-control risk remain open. (Answered on control status; open on trajectory.)
2. Is the June-2026 consumer softness cyclical or structural? How much of the NSPAC stumble is macro vs. Chewy-specific initiative slippage (management said “majority macro”)?
3. Will SBC decline as a % of revenue? Management has not committed to a declining SBC path; this is the swing factor between reported and real FCF.
4. What are CVC clinic unit economics at scale and the total capital commitment? ~$900 year-1 NSPAC is promising, but standalone clinic ROIC and the multi-year capex are undisclosed.
5. How is Chewy actually faring vs. Amazon in pet share, quarter to quarter? Management claims share gains; independent verification is thin.
6. What magnitude of “modest leverage” is coming, and to what use (buyback acceleration, M&A)?
7. Does Chewy Plus (membership) become a real NSPAC/retention driver, or stay margin-neutral optionality?

14. What Must Be True

Bull case — what must be true, and its falsification test.

• Autoship captivity holds and NSPAC re-accelerates above ~6% as health/vet/private-brand mix reasserts and the consumer normalizes.
• The adjusted-EBITDA-margin path to ~10% is achieved and increasingly cash-backed (SBC/revenue declines), so reported and real FCF converge upward.
• Chewy defends category share against Amazon/Walmart, keeping revenue growth ≥6–7%.
• Falsification test: if, over the next 2–4 quarters, Autoship-sales growth decelerates below ~mid-single-digits or adjusted EBITDA margin stalls below ~7.5% for a full year or active-customer growth drops below ~3%, the compounding thesis is broken and the stock is a value trap.

Bear case — what must be true, and its falsification test.

• Growth structurally fades toward ~3–4% as the pet category matures and the generalists take share.
• Margin expansion stalls near 7–8% (ads taper + fuel + gross-margin moderation), and SBC keeps “owner” FCF ~half of reported.
• The dual-class/sponsor overhang and no-wide-moat ceiling keep the multiple depressed.
• Falsification test: if NSPAC growth re-accelerates above ~6% and Chewy prints ~8%+ adjusted EBITDA margin while SBC/revenue falls year-over-year, the “value trap / cash-flow mirage” thesis is wrong and the business is compounding real per-share cash — warranting a re-rate.

The crux: both cases agree the business is real, net-cash, and FCF-positive. They disagree on (1) whether NSPAC/growth re-accelerates and (2) whether the SBC-adjusted economics justify more than the current ~0.66x sales. Watch NSPAC and SBC/revenue above all else.

15. Source Appendix

See the accompanying CHWY_source_appendix.md (Appendix B in the combined report) for the full source list. Primary sources: Chewy FY2025 Form 10-K and prior 10-Ks/10-Qs (SEC EDGAR, CIK 0001766502); Q4-FY2025 (Mar 25, 2026) and Q1-FY2026 (Jun 10, 2026) earnings calls and releases; DEF 14A proxy. Quantitative data: ROIC.ai (financials, ratios, enterprise value, valuation multiples), AZI (news feed, own-history valuation percentiles, 5-year price CSV), FactorsToday (factor loadings, risk-adjusted track record). Internal context: “Chewy and Zooplus — scuttleblurb” and historical Chewy transcripts , used as dated framing only. Facts cited to primary filings where material; management commentary treated as hypothesis and validated against filings and financials.

APPENDIX A — Standard Diligence Questionnaire

Chewy, Inc. (NYSE: CHWY) — as of 2026-07-04. Answers grounded in the underlying analysis; Fact / Interpretation / Assumption labels applied where material. Chewy’s fiscal year ends late January/early February; “FY2025” = year ended Feb 1, 2026.

General

What thoughtful questions have other investors asked about this company? The recurring debates: (1) Is Autoship a durable moat or just convenience that Amazon/Walmart can replicate with Subscribe & Save? (2) How much of the “free cash flow” is real once ~$298M of SBC is deducted? (3) Can NSPAC keep compounding as the consumer trades down, or has the growth algorithm structurally broken? (4) Is Chewy Vet Care a genuine TAM-expander with attractive unit economics, or a capital-intensive distraction? (5) What is the endgame for BC Partners’ ~88% voting control and its multi-year selldown? (6) Does the margin path to 10% adjusted EBITDA hold once sponsored-ads growth tapers? These are the right questions; this memo argues (2) and (3) are the swing factors.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Margins are at a cyclical/structural low-to-mid point on a rising trajectory — GAAP operating margin just reached 2.0% against a 10% adjusted-EBITDA target, so earnings power is early, not peaked. Revenue growth, by contrast, is near a cyclical low (mid-single-digit, guided down in June 2026 on consumer softness). So: depressed growth, early-stage margins.

Driven by external environment or internal actions? Both. The margin expansion is overwhelmingly internal (mix shift, sponsored ads, private brands, opex discipline, automation) — high-quality and self-directed. The recent revenue disappointment is largely external (a “discerning consumer,” premiumization/attach pressure), which management attributes “majority to the macro.”

How stable are revenues? Very stable by retail standards — ~84% of net sales are recurring Autoship of non-discretionary consumables/meds, with a negative working-capital cycle. This is the single best structural feature of the business.

Outlook for products/services; how big is the market? U.S. pet spending is large (~$150B+) and resilient, but now growing only low-single-digits (volume-driven, little pricing). Chewy’s incremental TAM expansion is in pet health/vet care (~$40B+ in-clinic). Interpretation: growing market, but the days of double-digit category growth are over; Chewy’s growth must come from share gains + NSPAC + health, not a rising tide.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Roughly stable-to-slightly-less-intense than the 2021 peak (promotional environment rationalized, weak players retrenched), but permanently pressured by Amazon and Walmart, who will never let online pet become a high-margin oligopoly.

How profitable is the business (ROIC, ROE)? Fact/Interpretation: Conventional ROIC/ROE are distorted by a tiny/negative equity base (accumulated deficit −$1.36B). The honest read is FCF conversion and incremental margins (~19% incremental operating margin) — decent and improving, but net margin is only 1.8%. This is a capital-light, low-margin model, not a high-return-on-capital compounder in the classic sense.

How profitable is the industry; barriers to entry? Moderate. Barriers to scaled online pet retail are real (fulfillment network, negative working capital, brand/service, data/retail-media scale), but not insurmountable to the generalist giants who already have them. Specialty peers (Petco) are weaker; the threat is horizontal, not vertical.

Can the business be easily understood? Yes — a first-party online pet retailer with a subscription overlay and emerging health/services adjacencies. Straightforward.

Can it be undermined by foreign low-cost labor? No — U.S. domestic e-commerce/logistics; not labor-arbitrage exposed. Tariff exposure on imported hardgoods/supplies is a modest, manageable input-cost risk.

Do brands matter? Nature of competition? Switching costs? Chewy’s own brand/service reputation matters and drives retention; the products it resells are largely commoditized national brands (limited pricing power, hence the private-brand push). Competition is on convenience, price parity, assortment, and service. Switching costs are real but moderate — an established Autoship relationship (saved pet profiles, meds, cadence) is sticky, but a determined customer can move to Amazon.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The customer base / Autoship annuity and the sponsored-ads/retail-media franchise are valuable intangibles not on the balance sheet — the real economic assets. Book value (~$1.2/share) is meaningless as a value anchor.

Off-balance-sheet liabilities? Operating/finance leases for fulfillment (finance-lease debt ~$519M is on-balance-sheet). No unusual off-balance-sheet exposure identified. Note the new $600M term loan (June 2026).

How conservative is the accounting? Reasonably clean, but with two calibration points: (1) heavy reliance on adjusted EBITDA and adjusted net income that add back ~$298M SBC — legitimate as reported, but the SBC is a real economic cost; (2) FY2024 GAAP net income was inflated by a one-time ~$241M deferred-tax-asset release. Normalize both. Reported “free cash flow” is defined conventionally (OCF − capex) but is struck after the SBC add-back.

How CapEx-hungry is the business? Not very — capex ~1% of sales (~$129M). Fulfillment automation and CVC clinics add some, but this is a genuinely asset-light model.

Capital Allocation & Management

How much FCF; how is it used; philosophy? ~$562M reported FCF (FY2025, a record); net of SBC ~$265M. Uses: buybacks (~$257M FY2025, ~$200M Q1 FY2026), on-strategy tuck-in M&A (Modern Animal, SmartPak), and P&L reinvestment. Philosophy: convert ≥80% of profitability to FCF, reinvest in high-ROI initiatives, return the rest via buyback. Interpretation: the buyback largely offsets SBC dilution and absorbs BC Partners’ selldown rather than shrinking the float.

Significant acquisitions recently? Only small, on-strategy tuck-ins (Modern Animal, SmartPak) plus organic CVC clinic buildout. No large or dilutive deals — a positive.

Buying back shares? Yes (~$257M FY2025, ramping in FY2026), but net of ~$298M SBC the share count is roughly flat (~407M→~409M over five years).

Issuing large amounts of stock to insiders? SBC is high (~2.4% of revenue, ~$298M/yr) — a material, ongoing transfer to employees, the key quality-of-earnings issue.

Compensation / incentive alignment. Open Question / mild concern: SBC is large; CEO owns ~1% (Class A only). No open-market insider buying in two years. Controlled by BC Partners (88% votes) via super-voting Class B — minority holders have limited governance leverage.

Motivations of management. CEO Sumit Singh has driven the profitable-growth pivot competently. But heavy C-suite churn (CFO, CAO, CTO all changed in ~12 months) and sponsor control temper confidence in stability.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a U.S. C-corp common stock (dual-class A/B); standard 1099 treatment.

Dividend policy? No dividend. Capital return is via buyback only. Appropriate at this stage.

How profitable is the business? GAAP net margin 1.8%; adjusted EBITDA margin 5.7% (FY2025), targeting 10%. Low-margin reseller with a rising, high-quality mix.

Is net income diverging from cash from operations? Yes — favorably in direction (OCF $692M > net income $223M, driven by D&A, SBC add-back, and negative working capital), but the divergence is substantially the ~$298M SBC add-back, which is the crux of the quality-of-earnings debate.

Risks & Downside

What would cause the stock to decline? Further NSPAC/growth deceleration; Amazon/Walmart share/price pressure; margin-path stall; consumer weakness proving structural; SBC keeping real FCF low; continued BC Partners selldown pressure; a debt-funded misstep.

Risk of catastrophic loss? Very low. Net-cash (pre-term-loan), FCF-positive, no solvency risk, non-discretionary demand.

Chance of a total loss? Negligible absent a multi-year competitive collapse. The realistic downside is a slow de-rating / value-trap outcome, not a zero.

Recent News & Events

Has the business environment changed recently? Yes — the June 10, 2026 Q1 print: an EPS/margin beat but a cut FY2026 revenue guide ($13.6–13.75B → $13.4–13.55B) on a “discerning consumer,” sending the stock to 2-year lows and triggering broad analyst price-target cuts (to $24–36). Margin guidance was held.

Significant acquisitions / accounting changes? Small tuck-ins (Modern Animal, SmartPak). FY2024 one-time ~$241M DTA release. First term debt ($600M, June 2026).

Recent changes — markets, facilities, management? New automated fulfillment (Houston next-gen), CVC clinic expansion, Chewy Plus membership, new private-brand lines (Get Real, Chewy Made), CFO/CAO/CTO changes, and the new $600M term loan.

APPENDIX B — Source Appendix

Chewy, Inc. (NYSE: CHWY) — research as of 2026-07-04. Primary sources prioritized over secondary. Facts cited to primary filings where material; management commentary treated as hypothesis and validated against filings/financials.

Primary — SEC filings (EDGAR, CIK 0001766502)

• Form 10-K, FY2025 (fiscal year ended Feb 1, 2026; filed 2026-03-25) — financials, segment/KPI disclosure, risk factors, share-repurchase and equity notes, tax footnote (DTA release), controlled-company disclosure. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001766502
• Form 10-Q, Q1 FY2026 (period ended May 3, 2026; filed 2026-06-10) — quarterly results, buyback authority, guidance context.
• DEF 14A proxy (filed 2026-05-22; record date 2026-05-13) — dual-class share counts (Class A ~232.5M / Class B ~176.5M), BC Partners ownership (~43% economics / ~88% votes), controlled-company exemptions, board composition, pledge disclosure, executive/director holdings.
• Prior 10-Ks / 10-Qs (FY2020–FY2024) — five-year revenue, gross-margin, SBC, and FCF history.
• 8-Ks (selected, last ~2 years): buyback authorizations ($500M May 2024; +$500M Apr 2026); CFO transition (David Reeder resignation Jul 2025; Christopher Deppe appointment Feb 2026); CAO removal and CTO departure (Jan–Feb 2026); earnings releases (Item 2.02, Mar 25 & Jun 10, 2026); $600M senior secured term loan (Term Loan Credit Agreement dated 2026-06-23, 8-K filed 2026-06-24).
• Form 4 corpus (2024-06 → 2026-06): ~97 filings; codes A (grants), F (tax withholding), S (sales) — zero code P (open-market purchases). Insider holdings per DEF 14A.
• Schedule 13G/A (BC Partners chain, filed 2025-11-10) — Class B ownership.

Primary — earnings calls / management commentary

• Q4 & FY2025 earnings call (Mar 25, 2026) — CEO Sumit Singh, CFO Chris Deppe: FY2025 results ($719M adj EBITDA / 5.7%; $562.4M record FCF; 21.3M active customers; Autoship 83.3% FY / 84% Q4; NSPAC $591), FY2026 guidance framework, margin/private-brand/vet-care commentary.
• Q1 FY2026 earnings call (Jun 10, 2026) — Q1 results (net sales ~$3.36B +7.7%; 21.5M active customers +3.6%; NSPAC $597; Autoship 84.4%; adj EBITDA 7.5%); FY2026 revenue-guidance cut and “discerning consumer” commentary; Modern Animal/SmartPak references; Chewy Plus; CVC (~$900 year-1 NSPAC, ~40% new-to-Chewy).

Quantitative data providers (third-party; reconciled to filings)

• ROIC.ai — income statement, balance sheet, cash flow, profitability/valuation ratios, enterprise value, valuation multiples (FY2019–FY2025). Third-party aggregated; EDGAR/10-K primary where they differ.
• AZI (azitrading.com) — company news feed (Jun 2026 earnings/analyst-action cluster); own-history valuation percentiles (P/S ~6th, composite ~16th); 5-year daily price CSV (adjusted OHLCV, EMAs, beta/alpha).
• FactorsToday (factorstoday.com) — factor loadings (Market ~1.20, Online Retail ~1.01, SmallSize ~0.77; negative Momentum/DividendYield), risk-adjusted leaderboard (all horizons negative; ~−84% max drawdown), stock-info (beta ~1.06, RS 12m ~−50%).

Public secondary / industry

• Sell-side price-target actions post-Q1 FY2026 (Baird, Barclays, TD Cowen, RBC, Goldman, JPMorgan, UBS, Citizens, Needham) — via AZI news feed; used only for consensus framing.
• U.S. pet-industry spend and e-commerce-penetration context (trade/industry estimates); management’s stated TAM figures (~$54B pet health, ~$40B in-clinic).
• Chewy price/IPO history (IPO Jun 14, 2019 at $22; ATH close $118.69 on Feb 12, 2021; ATL close $14.99 on Apr 30, 2024) — from the AZI price CSV.

Note on fiscal-year convention: Chewy labels the year ended Feb 1, 2026 as “FY2025.” Some data providers (e.g., ROIC.ai) label the same period “FY2026.” This memo uses Chewy’s convention throughout.